Your browser doesn't support javascript.
loading
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.
Liu, Jing; Rozeman, Elisa A; O'Donnell, Jake S; Allen, Stacey; Fanchi, Lorenzo; Smyth, Mark J; Blank, Christian U; Teng, Michele W L.
Afiliación
  • Liu J; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Rozeman EA; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • O'Donnell JS; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Allen S; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Fanchi L; School of Medicine, University of Queensland, Herston, Queensland, Australia.
  • Smyth MJ; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
  • Blank CU; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Teng MWL; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Oncoimmunology ; 8(2): e1546068, 2019.
Article en En | MEDLINE | ID: mdl-30713806
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Oncoimmunology Año: 2019 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Oncoimmunology Año: 2019 Tipo del documento: Article País de afiliación: Australia